Literature DB >> 24284057

Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?

Richard J Lee1, Matthew R Smith.   

Abstract

Treatment with cabozantinib, an inhibitor of MET and VEGFR2 signaling, has demonstrated clinical benefit in early trials in men with metastatic prostate cancer. Preclinical evidence suggests that cabozantinib can kill cancer cell seeds while disrupting angiogenesis and stromal cells in the metastatic soil. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24284057      PMCID： PMC3966545          DOI： 10.1158/1078-0432.CCR-13-2636

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Cabozantinib in progressive medullary thyroid cancer.

Authors:  Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

2.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Authors:  David C Smith; Matthew R Smith; Christopher Sweeney; Aymen A Elfiky; Christopher Logothetis; Paul G Corn; Nicholas J Vogelzang; Eric J Small; Andrea L Harzstark; Michael S Gordon; Ulka N Vaishampayan; Naomi B Haas; Alexander I Spira; Primo N Lara; Chia-Chi Lin; Sandy Srinivas; Avishay Sella; Patrick Schöffski; Christian Scheffold; Aaron L Weitzman; Maha Hussain
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

3.  Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Authors:  Jinlu Dai; Honglai Zhang; Andreas Karatsinides; Jill M Keller; Kenneth M Kozloff; Dana T Aftab; Frauke Schimmoller; Evan T Keller
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

Review 4.  Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.

Authors:  Richard J Lee; Matthew R Smith
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

5.  A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

Authors:  Richard J Lee; Philip J Saylor; M Dror Michaelson; S Michael Rothenberg; Malgorzata E Smas; David T Miyamoto; Carol A Gurski; Wanling Xie; Shyamala Maheswaran; Daniel A Haber; Jonathan G Goldin; Matthew R Smith
Journal:  Clin Cancer Res       Date:  2013-04-03       Impact factor: 12.531
  5 in total
  5 in total

Review 1.  Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.

Authors:  Metin Kurtoglu; Nicole N Davarpanah; Rui Qin; Thomas Powles; Jonathan E Rosenberg; Andrea B Apolo
Journal:  Clin Genitourin Cancer       Date:  2015-03-05       Impact factor: 2.872

Review 2.  Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?

Authors:  Alessandra Modena; Francesco Massari; Chiara Ciccarese; Matteo Brunelli; Matteo Santoni; Rodolfo Montironi; Guido Martignoni; Giampaolo Tortora
Journal:  Target Oncol       Date:  2016-08       Impact factor: 4.493

3.  Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89Zr-labeled ramucirumab.

Authors:  Miao Li; Dawei Jiang; Todd E Barnhart; Tianye Cao; Jonathan W Engle; Weiyu Chen; Weibo Cai
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 4.  Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers.

Authors:  Aude I Ségaliny; Marta Tellez-Gabriel; Marie-Françoise Heymann; Dominique Heymann
Journal:  J Bone Oncol       Date:  2015-01-23       Impact factor: 4.072

5.  Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.

Authors:  Andrea B Apolo; Rosa Nadal; Daniel M Girardi; Scot A Niglio; Lisa Ley; Lisa M Cordes; Seth M Steinberg; Olena Sierra Ortiz; Jacqueline Cadena; Carlos Diaz; Marissa Mallek; Nicole N Davarpanah; Rene Costello; Jane B Trepel; Min-Jung Lee; Maria J Merino; Mohammad Hadi Bagheri; Paul Monk; William D Figg; James L Gulley; Piyush K Agarwal; Vladimir Valera; Heather J Chalfin; Jennifer Jones; Howard Streicher; John J Wright; Yangmin M Ning; Howard L Parnes; William L Dahut; Donald P Bottaro; Primo N Lara; Biren Saraiya; Sumanta K Pal; Mark N Stein; Amir Mortazavi
Journal:  J Clin Oncol       Date:  2020-09-11       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.